WO2022202762A1 - 抗菌抗ウイルス剤、コーティング組成物、樹脂組成物、コーティング層及び成形体 - Google Patents

抗菌抗ウイルス剤、コーティング組成物、樹脂組成物、コーティング層及び成形体 Download PDF

Info

Publication number
WO2022202762A1
WO2022202762A1 PCT/JP2022/013002 JP2022013002W WO2022202762A1 WO 2022202762 A1 WO2022202762 A1 WO 2022202762A1 JP 2022013002 W JP2022013002 W JP 2022013002W WO 2022202762 A1 WO2022202762 A1 WO 2022202762A1
Authority
WO
WIPO (PCT)
Prior art keywords
molybdenum trioxide
antibacterial
particles
antiviral agent
trioxide particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2022/013002
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
榕輝 高
孝典 渡辺
幸介 藤田
俊介 河中
厚 中村
直人 矢木
建軍 袁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DIC Corp
Original Assignee
DIC Corp
Dainippon Ink and Chemicals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DIC Corp, Dainippon Ink and Chemicals Co Ltd filed Critical DIC Corp
Priority to CN202280023637.5A priority Critical patent/CN117042613A/zh
Priority to JP2023509172A priority patent/JPWO2022202762A1/ja
Publication of WO2022202762A1 publication Critical patent/WO2022202762A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • A01N25/10—Macromolecular compounds
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P1/00—Disinfectants; Antimicrobial compounds or mixtures thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01P—BIOCIDAL, PEST REPELLANT, PEST ATTRACTANT OR PLANT GROWTH REGULATORY ACTIVITY OF CHEMICAL COMPOUNDS OR PREPARATIONS
    • A01P3/00—Fungicides
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G39/00—Compounds of molybdenum
    • C01G39/02—Oxides; Hydroxides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D201/00—Coating compositions based on unspecified macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
    • C09D5/14—Paints containing biocides, e.g. fungicides, insecticides or pesticides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D7/00—Features of coating compositions, not provided for in group C09D5/00; Processes for incorporating ingredients in coating compositions
    • C09D7/40—Additives
    • C09D7/60—Additives non-macromolecular
    • C09D7/61—Additives non-macromolecular inorganic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to an antibacterial and antiviral agent, a coating composition, a resin composition, a coating layer and a molded article.
  • This application claims priority based on Japanese Patent Application No. 2021-050496 filed in Japan on March 24, 2021, the content of which is incorporated herein.
  • Conventional antibacterial/antiviral agents include photocatalyst-based ( TiO2 , etc.) and metal-based (Ag, etc.).
  • TiO2 photocatalyst-based
  • Au metal-based
  • Ag and silver compounds have problems such as stability and activity against non-enveloped viruses.
  • Patent Document 1 discloses an antiviral agent containing MoO 3 as an active ingredient. According to this antiviral agent, regardless of the presence or absence of a viral envelope, it exhibits high antiviral activity and is solid-state. It is believed to exert antiviral activity.
  • Patent Document 2 discloses a composite material having an antibacterial effect using a molybdenum compound.
  • JP 2019-182846 A Japanese Patent No. 5437809
  • the present invention was made to solve the above problems, and provides an antibacterial and antiviral agent that has antibacterial activity and/or antiviral activity and has a reduced effect on the appearance of the object to which it is applied. intended to
  • the present invention has the following aspects.
  • the molybdenum trioxide particles contain aggregates of primary particles containing a crystal structure;
  • the peak intensity of the molybdenum trioxide particles attributed to the (011) plane of the ⁇ crystal of MoO3 is 0.1 or more, any one of the above (1) to (5)
  • the peak intensity of the molybdenum trioxide particles attributed to the (011) plane of the ⁇ crystal of MoO 3 , the ratio ( ⁇ (011)/ ⁇ (021)) to the peak intensity attributed to the (021) plane of the ⁇ crystal of MoO 3 is 10.0 or less.
  • (11) A resin composition containing the antibacterial and antiviral agent according to any one of (1) to (7) above and a resin.
  • (12) A molded article obtained by molding the resin composition according to (11) above.
  • an antibacterial and antiviral agent that has antibacterial activity and/or antiviral activity and has a reduced effect on the appearance of the object to which it is applied.
  • An antibacterial antiviral agent of an embodiment contains molybdenum trioxide particles, the molybdenum trioxide particles have a specific surface area of 10 m 2 /g or more as measured by the BET method, and have antibacterial activity and/or antiviral activity. .
  • antibacterial and/or antiviral may be referred to as "antibacterial and antiviral.”
  • an antibacterial agent containing molybdenum trioxide particles, the molybdenum trioxide particles having a specific surface area of 10 m 2 /g or more as measured by the BET method, and having antibacterial activity.
  • an antiviral agent containing molybdenum trioxide particles, the molybdenum trioxide particles having a specific surface area of 10 m 2 /g or more as measured by the BET method, and having antiviral activity.
  • the molybdenum trioxide particles having a specific surface area of 10 m 2 /g or more as measured by the BET method are used as an antibacterial and antiviral agent.
  • use of the molybdenum trioxide particles having a specific surface area of 10 m 2 /g or more as measured by the BET method as an antibacterial agent is provided.
  • use of the molybdenum trioxide particles having a specific surface area of 10 m 2 /g or more as measured by the BET method as an antiviral agent is provided.
  • the antibacterial antiviral agent of the embodiment contains molybdenum trioxide particles as an active ingredient. It is believed that molybdenum trioxide particles provide an acidic state due to a small amount of adsorbed water present on the particle surface, and exhibit excellent antibacterial and antiviral effects.
  • Antibacterial activity means having the effect of suppressing the growth of bacteria.
  • Antiviral activity means having the effect of reducing the number of infectious viruses.
  • An activity value such as an infectivity titer may be used as an indicator of the proliferation and number.
  • the antibacterial activity and antiviral activity of the antibacterial antiviral agent of the embodiment can be evaluated, for example, by preparing a composition containing molybdenum trioxide particles as an active ingredient of the antibacterial antiviral agent, and using the coating layer of the composition as a test sample, can be confirmed.
  • Antiviral activity can be confirmed by known antiviral tests, for example, according to ISO21702, JIS L1922, or JIS R 1756 antiviral tests.
  • the antibacterial activity can be confirmed by a known antibacterial test, for example, according to JIS Z 2801, JIS L1902, or JIS R 1706 antibacterial tests.
  • compositions, coating layer, and molded article containing molybdenum trioxide particles as the active ingredient of the antibacterial and antiviral agent will be described later.
  • target bacteria examples include bacteria in general, such as Escherichia coli and Staphylococcus aureus.
  • target viruses include viruses in general, including various DNA viruses, RNA viruses, and bacteriophages, which are viruses that infect bacteria.
  • the antibacterial and antiviral agents of the embodiments exhibit more effective antibacterial and antiviral activity against bacteria or viruses in general whose growth is inhibited or whose numbers decrease under acidic conditions.
  • the molybdenum trioxide particles contained in the antibacterial antiviral agent of the embodiment have a specific surface area of 10 m 2 /g or more as measured by the BET method.
  • Conventional molybdenum trioxide particles having a specific surface area of less than 10 m 2 /g measured by the BET method can be used when applied to any surface, or when mixed with a medium, resin, etc. to form a composition. Appearance is likely to be affected, for example, the object or composition may appear whitish, the original color of the object to which it is applied may be impaired, or the transparency may be impaired.
  • the application target includes not only the target to which the composition is applied, but also components other than the molybdenum trioxide particles contained in the composition itself (for example, medium, resin, etc.).
  • the antibacterial and antiviral agent exhibits antibacterial activity and/or antiviral activity and is applicable to molybdenum trioxide particles having a specific surface area of 10 m 2 /g or more as measured by the BET method. It is compatible with the reduction of the influence on the appearance of
  • the surface area of the active substance is considered important.
  • the antibacterial and antiviral agents of the embodiments are considered to exhibit excellent antibacterial activity and/or antiviral activity because the molybdenum trioxide particles have a large specific surface area.
  • the molybdenum trioxide particles are considered to have a shape and size with a large specific surface area, it is presumed that the dispersibility in the composition is enhanced and the influence on the appearance is reduced.
  • the molybdenum trioxide particles contained in the antibacterial antiviral agent of the embodiment have a specific surface area measured by the BET method of 10 m 2 /g or more, preferably 20 m 2 /g or more, and 30 m 2 /g or more. It is more preferable to have When the specific surface area is equal to or higher than the lower limit, it is possible to improve the degree of compatibility between exhibiting antibacterial activity and/or antiviral activity and reducing the influence on the original appearance of the application target.
  • the specific surface area of the molybdenum trioxide particles measured by the BET method may be 300 m 2 /g or less, or may be 200 m 2 /g or less, because the production of the molybdenum trioxide particles is facilitated.
  • An example of the numerical range of the specific surface area of molybdenum trioxide particles measured by the BET method may be 10 m 2 /g or more and 300 m 2 /g or less, or 20 m 2 /g or more and 200 m 2 /g or less. 30 m 2 /g or more and 150 m 2 /g or less.
  • the specific surface area can be measured by the BET (Brunauer-Emmerit-Teller) method (adsorption gas: nitrogen) in accordance with JIS Z 8830.
  • the molybdenum trioxide particles have a large surface area, and from the viewpoint of exhibiting good antibacterial and antiviral activity, the molybdenum trioxide particles should have a median diameter D50 of 2000 nm or less as determined by a dynamic light scattering method. is preferred, 500 nm or less is more preferred, and 200 nm or less is even more preferred.
  • the median diameter D50 of the molybdenum trioxide particles determined by the dynamic light scattering method is preferably 10 nm or more, more preferably 20 nm or more, and even more preferably 40 nm or more.
  • the median diameter D50 determined by the dynamic light scattering method is preferably 10 nm or more and 2000 nm or less, more preferably 20 nm or more and 500 nm or less, and even more preferably 40 nm or more and 200 nm or less.
  • the median diameter D50 of the molybdenum trioxide particles is calculated from a volume-based cumulative particle size distribution measured using, for example, a dynamic light scattering particle size distribution analyzer.
  • the average particle size of the primary particles of the molybdenum trioxide particles of the embodiment is preferably 2000 nm or less, and 1000 nm or less, from the viewpoint that the surface area is large and the antibacterial and antiviral activity is well exhibited. is preferred, 500 nm or less is more preferred, and 200 nm or less is particularly preferred.
  • the average particle size of the primary particles of the molybdenum trioxide particles of the present embodiment may be 10 nm or more, 20 nm or more, or 40 nm or more.
  • An example of the numerical range of the average particle size of the primary particles of the molybdenum trioxide particles of the embodiment may be 10 nm or more and 2000 nm or less, 20 nm or more and 1000 nm or less, or 40 nm or more and 500 nm or less. It may be 40 nm or more and 200 nm or less, or 20 nm or more and 150 nm or less.
  • the average particle size of the primary particles of the molybdenum trioxide particles means that the molybdenum trioxide particles are photographed with a transmission electron microscope (TEM) or a scanning electron microscope (SEM) and aggregated on a two-dimensional image.
  • TEM transmission electron microscope
  • SEM scanning electron microscope
  • the major axis the longest Feret diameter observed
  • the minor axis the short Feret diameter perpendicular to the longest Feret diameter
  • the average value is defined as the primary particle diameter, the mean value of the primary particle diameters of 50 randomly selected primary particles.
  • the shape of the primary particles of the molybdenum trioxide particles of the embodiment in a two-dimensional image taken with a transmission electron microscope (TEM) can be visually observed or photographed to be particulate, spherical, plate-like (sheet-like), It may be needle-shaped, string-shaped, or ribbon-shaped, and may include combinations of these shapes.
  • the shape of the primary particles of the molybdenum trioxide powder may be ribbon-like or sheet-like having a nano-order thickness.
  • the content ratio of MoO3 as measured by X-ray fluorescence (XRF) with respect to the total mass of the molybdenum trioxide particles of the present embodiment is preferably 99.5 mass% or more with respect to the total detected peak intensity, and more It is preferably 99.65% by mass or more, more preferably 99.77% by mass or more, and particularly preferably 99.89% by mass or more.
  • the molybdenum trioxide particles of the present embodiment contain an aggregate of primary particles containing a molybdenum trioxide crystal structure, and the crystal structure preferably contains ⁇ crystals having an average crystallite size of 50 nm or less, and preferably 45 nm or less. It is more preferable to contain ⁇ -crystals of 40 nm or less, and it is particularly preferable to contain ⁇ -crystals of 35 nm or less.
  • the molybdenum trioxide particles of the present embodiment contain an aggregate of primary particles containing a molybdenum trioxide crystal structure, and the crystal structure preferably contains ⁇ -crystals having an average crystallite size of 5 nm or more, and preferably 10 nm or more.
  • the average crystallite size of ⁇ -crystals contained in the crystal structure of molybdenum trioxide is preferably 5 nm or more and 50 nm or less, more preferably 5 nm or more and 45 nm or less, still more preferably 10 nm or more and 40 nm or less, Especially preferably, it is 10 nm or more and 35 nm or less.
  • the average crystallite size of the crystals is within the above preferred range, the antibacterial and antiviral activity tends to be better.
  • the molybdenum trioxide particles have a large surface area and contain aggregates of primary particles containing a crystal structure of molybdenum trioxide from the viewpoint of exhibiting good antibacterial and antiviral activity, and the crystal structure is an average crystal It is preferable that the particle size contains ⁇ -crystals of 50 nm or less, and that the median diameter D50 of the primary particles determined by the dynamic light scattering method is 2000 nm or less.
  • the crystal structure of molybdenum trioxide may further include ⁇ crystals with an average crystallite size of 50 nm or less.
  • the crystal structure of molybdenum trioxide contains ⁇ crystals and ⁇ crystals, the antibacterial and antiviral activity tends to be better.
  • the molybdenum trioxide particles of the present embodiment contain an aggregate of primary particles containing a molybdenum trioxide crystal structure, and the crystal structure preferably contains ⁇ crystals having an average crystallite size of 50 nm or less, and preferably 45 nm or less. ⁇ -crystals of 40 nm or less is more preferable, and ⁇ -crystals of 30 nm or less are particularly preferable.
  • the molybdenum trioxide particles of the present embodiment contain aggregates of primary particles containing a crystal structure of molybdenum trioxide, and the crystal structure preferably contains ⁇ crystals having an average crystallite size of 5 nm or more, and preferably 10 nm or more.
  • the average crystallite size of the ⁇ crystals included in the crystal structure of molybdenum trioxide is preferably 5 nm or more and 50 nm or less, more preferably 5 nm or more and 45 nm or less, still more preferably 10 nm or more and 40 nm or less, Especially preferably, it is 10 nm or more and 30 nm or less.
  • the average crystallite size of the ⁇ crystals is within the above preferred range, the antibacterial and antiviral activity tends to be better.
  • the ⁇ crystal structure of molybdenum trioxide is due to the presence of the peak of the (021) plane of the ⁇ crystal of MoO3 (2 ⁇ : around 27.32°_No.166363 (Inorganic Crystal Structure Database, ICSD)) , can be verified.
  • the ⁇ crystal structure is attributed to the (011) plane of the ⁇ crystal of MoO 3 in a profile obtained from powder X-ray diffraction (XRD) using Cu—K ⁇ rays as an X-ray source, (2 ⁇ : 23. It can also be confirmed by the presence of a peak near 01°, No. 86426 (inorganic crystal structure database, ICSD)).
  • the ⁇ crystal structure of molybdenum trioxide can also be confirmed by the presence of peaks at wavenumbers 773, 848 cm ⁇ 1 and 905 cm ⁇ 1 in the Raman spectrum obtained from Raman spectroscopy.
  • the ⁇ crystal structure of molybdenum trioxide can be confirmed by the presence of peaks at wavenumbers of 663, 816 cm ⁇ 1 and 991 cm ⁇ 1 .
  • the molybdenum trioxide particles of the present embodiment have a peak intensity attributed to the (011) plane of the ⁇ crystal of MoO 3 in a profile obtained from powder X-ray diffraction (XRD) using Cu—K ⁇ rays as an X-ray source.
  • the ratio ( ⁇ (011)/ ⁇ (021)) to the peak intensity attributed to the (021) plane of the ⁇ crystal of MoO 3 is preferably 0.1 or more, more preferably 0.2 or more. , is more preferably 0.4 or more.
  • the ratio ( ⁇ (011)/ ⁇ (021)) is preferably 10.0 or less.
  • the peak intensity attributed to the (011) plane of the ⁇ crystal of MoO 3 and the peak intensity attributed to the (021) plane of the ⁇ crystal of MoO 3 read the maximum intensity of the peak, respectively, and the ratio ( ⁇ (011 )/ ⁇ (021)).
  • the ratio ( ⁇ (011)/ ⁇ (021)) is preferably 0.1 to 10.0, more preferably 0.2 to 10.0. It is preferably from 0.4 to 10.0, and particularly preferably from 0.4 to 10.0. It is considered that the larger the ratio ( ⁇ (011)/ ⁇ (021)), the better the antibacterial and antiviral activity.
  • the molybdenum trioxide particles of the present embodiment have an intensity I of the peak due to Mo—O in the radial distribution function obtained from the extended X-ray absorption fine structure (EXAFS) spectrum of the K absorption edge of molybdenum.
  • the ratio (I/II) to the resulting peak intensity II is preferably greater than 1.1.
  • the ratio (I/II) is considered to be an indication that ⁇ crystals of MoO 3 are obtained in the molybdenum trioxide particles, and the larger the ratio (I/II), the better the antibacterial and antiviral activity. it is conceivable that.
  • the ratio (I/II) is preferably 0.1 or more, more preferably 0.5 or more, and particularly preferably 1.0 or more. .
  • the content of ⁇ crystals in the molybdenum trioxide particles of the embodiment is not particularly limited, but may be 80% or less, 50% or less, or 70% or less. From another aspect, the content of ⁇ crystals in the molybdenum trioxide powder of the present embodiment may be 20% or more and 100% or less, may be 50% or more and 100% or less, or may be 70% or more and 100% or less. % or less, 80% or more and 100% or less, or 100%.
  • the content of ⁇ -crystals of MoO 3 can be determined from the obtained profile data by the RIR (Reference Intensity Ratio) method.
  • MoO 3 ⁇ - crystal content (%) ( IA /KA)/(( IA / KA )+( IB / KB )) ⁇ 100 (2)
  • RIR values values listed in the ICSD database can be used, and integrated powder X-ray analysis software (manufactured by Rigaku, PDXL Version 2) can be used for analysis.
  • Each of the specific surface area, average particle size, MoO3 content, ⁇ (011)/ ⁇ (021), ratio (I/II), and ⁇ crystal content of the molybdenum trioxide particles of the present embodiment Values can be determined for aggregates of primary particles of molybdenum trioxide particles.
  • the molybdenum trioxide particles are preferably produced by ⁇ Method for producing molybdenum trioxide particles> described below.
  • the method for producing molybdenum trioxide particles of the present embodiment is the method for producing molybdenum trioxide particles of the previous embodiment, wherein a molybdenum oxide precursor compound is vaporized to form molybdenum trioxide vapor, and the molybdenum trioxide vapor is Including cooling steam. According to the method for producing molybdenum trioxide particles of the embodiment, it is possible to produce the molybdenum trioxide particles contained in the antibacterial antiviral agent of the embodiment.
  • a raw material mixture containing a molybdenum oxide precursor compound and a metal compound other than the molybdenum oxide precursor compound is fired to vaporize the molybdenum oxide precursor compound, Including forming molybdenum trioxide vapor, the ratio of the metal compound to 100% by mass of the raw material mixture is preferably 70% by mass or less in terms of oxide.
  • the method for producing molybdenum trioxide particles of the present embodiment can be suitably carried out using the production apparatus 1 shown in FIG.
  • FIG. 2 is a schematic diagram of an example of an apparatus used for producing molybdenum trioxide particles of this embodiment.
  • a production apparatus 1 includes a firing furnace 2 for firing a molybdenum oxide precursor compound or the raw material mixture to vaporize the molybdenum oxide precursor compound, and a firing furnace 2 connected to the molybdenum trioxide vaporized by the firing. It has a cross-shaped cooling pipe 3 for pulverizing steam and a collector 4 as a collecting means for collecting the molybdenum trioxide particles pulverized in the cooling pipe 3 . At this time, the firing furnace 2 and the cooling pipe 3 are connected through an exhaust port 5 .
  • the cooling pipe 3 is provided with an opening adjusting damper 6 for an outside air intake (not shown) at the left end, and an observation window 7 at the upper end.
  • the collection machine 4 is connected with an exhaust device 8 as a first air blowing means. When the exhaust device 8 exhausts the air, the collector 4 and the cooling pipe 3 are sucked, and outside air is blown to the cooling pipe 3 from the opening adjustment damper 6 of the cooling pipe 3 . That is, the cooling pipe 3 is passively blown with air by the exhaust device 8 having a suction function.
  • the manufacturing apparatus 1 may have an external cooling device 9, which makes it possible to arbitrarily control the cooling conditions of the molybdenum trioxide vapor generated from the kiln 2.
  • the molybdenum oxide precursor compound is not particularly limited as long as it is a precursor compound for forming molybdenum trioxide particles according to the present invention.
  • molybdenum oxide precursor compounds may be used alone or in combination of two or more.
  • the form of the molybdenum oxide precursor compound is not particularly limited.
  • it may be in the form of powder such as molybdenum trioxide, or may be in the form of liquid such as aqueous solution of ammonium molybdate.
  • it is in the form of powder, which is easy to handle and energy efficient.
  • molybdenum oxide precursor compound it is preferable to use commercially available ⁇ -crystalline molybdenum trioxide. Further, when ammonium molybdate is used as the molybdenum oxide precursor compound, it is converted to thermodynamically stable molybdenum trioxide by firing, so the molybdenum oxide precursor compound to be vaporized is the molybdenum trioxide. .
  • molybdenum trioxide is preferably contained from the viewpoint of easy control of the purity of molybdenum trioxide particles to be obtained, the average particle size of primary particles, and the crystal structure.
  • Molybdenum trioxide vapor can also be formed by firing a raw material mixture containing a molybdenum oxide precursor compound and a metal compound other than the molybdenum oxide precursor compound.
  • Metal compounds other than the molybdenum oxide precursor compound are not particularly limited, but are aluminum compounds, silicon compounds, titanium compounds, magnesium compounds, sodium compounds, potassium compounds, zirconium compounds, yttrium compounds, zinc compounds, copper compounds, and iron compounds. etc. Among these, aluminum compounds, silicon compounds, titanium compounds, and magnesium compounds are preferably used.
  • a molybdenum oxide precursor compound and a metal compound other than the molybdenum oxide precursor compound may sometimes form an intermediate. It can be vaporized in the form
  • metal compound other than the molybdenum oxide precursor compound among these, it is preferable to use an aluminum compound in order to prevent damage to the firing furnace.
  • a metal compound other than the compound may not be used.
  • Aluminum compounds include aluminum chloride, aluminum sulfate, basic aluminum acetate, aluminum hydroxide, boehmite, pseudoboehmite, transitional aluminum oxides ( ⁇ -aluminum oxide, ⁇ -aluminum oxide, ⁇ -aluminum oxide, etc.), Examples include ⁇ -aluminum oxide and mixed oxide aluminum having two or more crystal phases.
  • the content of the molybdenum oxide precursor compound with respect to 100% by mass of the raw material mixture is 5% by mass to 5% by mass. It is preferably 100% by mass, may be 10% by mass to 100% by mass, and may be 20% by mass to 100% by mass.
  • the firing temperature varies depending on the molybdenum oxide precursor compound, the metal compound, and the desired molybdenum trioxide particles used, it is usually preferable to set the temperature at which the intermediates can be decomposed.
  • the temperature is preferably 500° C. to 1500° C. , 600°C to 1550°C, more preferably 700°C to 1600°C.
  • the firing time is also not particularly limited, and can be, for example, 1 minute or more, 1 minute to 30 hours, 10 minutes to 25 hours, or 100 minutes to 20 hours. can be done.
  • the rate of temperature increase varies depending on the properties of the molybdenum oxide precursor compound used, the metal compound, and the desired molybdenum trioxide particles. is preferred, 1 to 50°C/min is more preferred, and 2 to 10°C/min is even more preferred.
  • the internal pressure in the firing furnace is not particularly limited, and may be a positive pressure or a reduced pressure. It is preferably done in A specific degree of reduced pressure is preferably -5000 to -10 Pa, more preferably -2000 to -20 Pa, and even more preferably -1000 to -50 Pa.
  • a specific degree of reduced pressure is preferably -5000 to -10 Pa, more preferably -2000 to -20 Pa, and even more preferably -1000 to -50 Pa.
  • the degree of pressure reduction is -5000 Pa or more, the high airtightness and mechanical strength of the firing furnace are not required excessively, and the manufacturing cost can be reduced, which is preferable.
  • the degree of pressure reduction is -10 Pa or less, clogging of the molybdenum oxide precursor compound at the discharge port of the firing furnace can be prevented, which is preferable.
  • the temperature of the gas to be blown is preferably 5 to 500°C, more preferably 10 to 100°C.
  • the blowing speed of the gas is preferably 1 to 500 L/min, more preferably 10 to 200 L/min, with respect to the effective volume of the firing furnace of 100 L.
  • the temperature of the vaporized molybdenum trioxide vapor varies depending on the type of molybdenum oxide precursor compound used, it is preferably 200 to 2000°C, more preferably 400 to 1500°C. If the vaporized molybdenum trioxide vapor has a temperature of 2000° C. or less, it tends to be easily pulverized by blowing outside air (0 to 100° C.) in a cooling pipe.
  • the discharge rate of molybdenum trioxide vapor discharged from the firing furnace depends on the amount of the molybdenum oxide precursor compound used, the amount of the metal compound, the temperature of the firing furnace, the blowing of gas into the firing furnace, and the diameter of the firing furnace exhaust port. can be controlled by
  • the discharge rate of molybdenum trioxide vapor from the kiln to the cooling pipes is preferably 0.001 to 100 g/min, more preferably 0.1 to 50 g/min, although it depends on the cooling capacity of the cooling pipes. more preferred.
  • the content of molybdenum trioxide vapor contained in the gas discharged from the firing furnace is preferably 0.01 to 1000 mg/L, more preferably 1 to 500 mg/L.
  • the molybdenum trioxide vapor is then cooled and pulverized. Cooling of the molybdenum trioxide vapor is performed by lowering the temperature of the cooling pipe.
  • the cooling means includes cooling by blowing gas into the cooling pipe, cooling by a cooling mechanism provided in the cooling pipe, and cooling by an external cooling device, as described above.
  • the cooling temperature (the temperature of the cooling pipe) is not particularly limited, but is preferably -100 to 600°C, more preferably -50 to 400°C.
  • the cooling rate of the molybdenum trioxide vapor is not particularly limited, it is preferably 100 to 100000°C/s, more preferably 1000 to 50000°C/s. There is a tendency that molybdenum trioxide particles having a smaller particle size and a larger specific surface area can be obtained as the cooling rate of the molybdenum trioxide vapor increases.
  • the temperature of the blown gas is preferably -100 to 300°C, more preferably -50 to 100°C.
  • the blowing speed of the gas is preferably 0.1 to 20 m 3 /min, more preferably 1 to 10 m 3 /min.
  • a gas blowing speed of 0.1 m 3 /min or more is preferable because a high cooling speed can be achieved and clogging of the cooling pipes can be prevented.
  • the gas blowing speed is 20 m 3 /min or less, the expensive first blowing means (exhaust fan, etc.) becomes unnecessary, which is preferable because the manufacturing cost can be reduced.
  • the particles obtained by cooling the molybdenum trioxide vapor are transported to and collected by the collector.
  • the particles obtained by cooling the molybdenum trioxide vapor may be fired again at a temperature of 100 to 320°C.
  • the molybdenum trioxide particles obtained by the method for producing molybdenum trioxide particles of the present embodiment may be fired again at a temperature of 100 to 320°C.
  • the firing temperature for the second firing may be 120 to 280.degree. C. or 140 to 240.degree.
  • the firing time for the second firing can be, for example, 1 min to 4 hours, 10 min to 5 hours, or 100 min to 6 hours.
  • the molybdenum trioxide crystal size grows and the ⁇ crystal structure in the molybdenum trioxide particles disappears.
  • molybdenum trioxide particles of the embodiment In general, to obtain particles with a large specific surface area, it is possible to reduce the size of the particles, but processing to reduce the size of the particles takes time and costs.
  • the method for producing molybdenum trioxide particles of the embodiment it is possible to efficiently produce molybdenum trioxide particles having a large specific surface area, as exemplified in the antibacterial antiviral agent of the embodiment.
  • the molybdenum trioxide particles produced by the method for producing molybdenum trioxide particles of the embodiment have antibacterial activity and/or antiviral activity, and can reduce the effect on the appearance of the application target.
  • Molybdenum trioxide particles according to embodiments can be blended with optional ingredients to provide a composition. Since the composition of the embodiment contains the molybdenum trioxide particles in the above antibacterial and antiviral agent, it has antibacterial and antiviral activity and can reduce the effect on the appearance of the object to which it is applied.
  • composition of the present invention a coating composition containing the antimicrobial antiviral agent of the embodiment, a binder, and a dispersion medium is exemplified.
  • one embodiment of the composition of the present invention is a coating composition containing molybdenum trioxide particles, a binder, and a dispersion medium.
  • a coating composition containing the antibacterial antiviral agent of the embodiment and an active energy ray-curable resin is exemplified.
  • a coating composition containing molybdenum trioxide particles and an active energy ray-curable resin is exemplified as an embodiment of the composition of the present invention.
  • a resin composition containing the antibacterial antiviral agent of the embodiment and a resin is exemplified.
  • a resin composition containing molybdenum trioxide particles and a resin is exemplified as an embodiment of the composition of the present invention.
  • molybdenum trioxide particles examples include those exemplified for the antibacterial and antiviral agents of the above embodiments.
  • the coating composition of one embodiment of the invention comprises a binder. Since the binder forms a film and exerts adhesion to the object to which it is applied, it effectively immobilizes the antibacterial and antiviral agent according to the embodiment, making it practical as a film or a composite material having a film on the surface. be able to.
  • Both an organic binder and an inorganic binder can be used as the binder.
  • inorganic binders include silica-based materials such as colloidal silica, alkali silicates, alkoxysilanes and hydrolysates thereof, and oxides, hydroxides and peroxides of metals selected from Ti, Al and Zr. An oxide or an organic compound can be mentioned.
  • Organic binders include, for example, polymer binders.
  • Both natural resins and synthetic resins can be used for the polymer binder.
  • synthetic resins include acrylic resins, phenolic resins, polyurethane resins, acrylonitrile/styrene copolymer resins, acrylonitrile/butadiene/styrene copolymer (ABS) resins, polyester resins, epoxy resins, and silicone resins.
  • the content of the binder may be determined as appropriate, but it is usually about 10 to 99% by mass based on the total solid mass of the coating composition.
  • the coating composition of one embodiment of the invention comprises a dispersion medium.
  • the dispersion medium may be either an aqueous medium or an oily medium, and may be appropriately selected from the viewpoint of compatibility and mixability with the binder used.
  • the solid content concentration relative to the total mass of the coating composition is usually about 30 to 80% by mass, and can be appropriately set depending on the viscosity suitable for the coating method, the desired thickness of the coating layer, and the like.
  • dispersion media examples include water, 1-butanol, isobutanol, 1-pentanol, 2-methyl-2-pentanol, 3-methyl-3-pentanol, methyl ethyl ketone, methanol, ethanol, n-propyl alcohol, Monofunctional alcohols such as isopropyl alcohol, various diols, polyhydric alcohols such as glycerin, ethylene glycol, 1,2-propanediol, 1,3-propanediol, 1,4-butanediol, 1,6-hexanediol, 1 ,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,12-dodecanediol, propylene glycol, 1,2-butanediol, 3-methyl-1,3-butanediol, 1,2-pentane Diols, diols such as 2-
  • the coating composition of the embodiment can also be provided as a solventless coating composition.
  • the coating composition of the embodiment can contain an active energy ray-curable resin.
  • resins that can be cured by irradiation with active energy rays include acrylic acrylates that have functional groups that are reactive to active energy rays, such as (meth)acryloyl groups in the side chains, and active energy rays such as styryl groups in the side chains.
  • a solvent-free coating composition When preparing a solvent-free coating composition, it may contain polymers, oligomers, and monomers having reactivity due to irradiation with active energy rays such as (meth)acryloyl groups, and further hydroxyacetophenone and aminoacetophenone.
  • active energy rays such as (meth)acryloyl groups
  • benzoin, benzoin ether, benzyl ketal, benzophenone, thioxanthone, phosphine oxide, glyoxyester, oxyacetate and the like can be used as photopolymerization initiators.
  • An oligomer may be a polymer having a repeating number of monomers of about 2 to 20, and is also called a prepolymer.
  • the oligomer preferably has 2 to 6 reactive double bonds at its terminals, and exists in a wide range of states from low-viscosity liquid to semi-solid.
  • Representative oligomers include urethane acrylates, epoxy acrylates, polyester acrylates, and the like.
  • the coating composition may contain optional components other than those described above within a range that does not impair the object of the present invention.
  • Optional components include coloring pigments, extender pigments, delustering agents, preservatives, antifoaming agents, dispersing agents, leveling agents, thickeners and the like.
  • a coating layer of the composition can be exemplified as an example of the composition of the embodiment.
  • the coating layers of embodiments can be formed using the compositions of the above embodiments. More specifically, the coating layer of the embodiment can be formed by forming a coating film of the composition of the above embodiment and curing the coating film.
  • a coating layer can be obtained by coating the composition of the embodiment onto a substrate such as a plastic material, paper, a molded product, a film substrate, or a packaging material by a general coating method. Specific coating methods include gravure roll coating (gravure coater), flexo roll coating (flexo coater), reverse roll coating, wire bar coating, lip coating, air knife coating, curtain flow coating, spray coating, and dip coating. A coating method or the like can be adopted.
  • a coating layer may also be provided on the surface of the substrate by impregnating the substrate with the composition.
  • the content of molybdenum trioxide particles may be 1 g/m 2 or less, or 0.01 g/m 2 or more and 1 g/m 2 or more. It may be 2 or less.
  • the thickness of the coating layer may be appropriately adjusted depending on the application, the material of the base material, etc., and can be exemplified in the range of 0.1 ⁇ m to 100 ⁇ m.
  • the resin composition of the embodiment can contain molybdenum trioxide particles and a resin.
  • a thermoplastic resin or a thermosetting resin is preferable as the resin.
  • Resins are not particularly limited, but polycarbonate resins, polyamide resins, PET resins, PBT resins, AS resins, PS resins, PMMA resins, ABS resins, acrylic resins, urethane resins, acrylic urethane resins, polyester resins, epoxy resins, and the like. mentioned.
  • the resin composition of the embodiment can optionally contain optional components such as an antioxidant, a weathering agent, a flame retardant, an antistatic agent, and a lubricant.
  • the resin composition of the embodiment can be obtained by uniformly mixing the molybdenum trioxide particles, the resin, and the optional components exemplified above, and the method is not limited. A method of preparing a high-concentration so-called masterbatch and then diluting it with various resins or the like for homogenization may also be used.
  • a molded article obtained by molding the resin composition of the embodiment is exemplified.
  • the manufacturing method or shape of the molded product There are no particular restrictions on the manufacturing method or shape of the molded product, and injection molded products, transfer molded products, compression molded products, cast molded products, laminated molded products, melt spun fibers, etc., can be used depending on the resin type and application. can be selected as appropriate.
  • the coating layer and molded body of the embodiment are used as materials having antibacterial and antiviral activity, such as mobile phone exteriors and touch panel exteriors; furniture or fixtures such as handrails, doorknobs, and washbasins; push buttons such as elevator buttons; It can be used in a wide range of applications, such as interior decoration of interiors, buses, houses, etc.; packaging materials, etc., especially as surface materials formed on their surfaces.
  • the solution is similarly prepared, and a particle diameter in the range of 0.015 to 500 ⁇ m is measured using a laser diffraction particle size distribution analyzer (SALD-7000 manufactured by Shimadzu Corporation). The distribution was measured and the median diameter D50 was calculated.
  • SALD-7000 laser diffraction particle size distribution analyzer
  • molybdenum trioxide particles constituting the molybdenum trioxide powder are dispersed in ethanol, and are observed under a transmission electron microscope (TEM, JEM1400 manufactured by JEOL).
  • the ⁇ crystal structure of molybdenum trioxide is attributed to the (011) plane of the ⁇ crystal of MoO 3 in the powder X-ray diffraction (XRD) profile measured under these conditions. Confirmed by the presence of a peak at 86426 (Inorganic Crystal Structure Database, ICSD).
  • the content of ⁇ -crystals of MoO 3 in the mixture of ⁇ -crystals and ⁇ -crystals of MoO 3 was determined from the obtained profile data by the RIR (Reference Intensity Ratio) method.
  • Nano-sized molybdenum trioxide was produced using a RHK simulator (manufactured by Noritake Co., Ltd.) as a firing furnace and a VF-5N dust collector (manufactured by Amano Co., Ltd.) as a dust collector.
  • a RHK simulator manufactured by Noritake Co., Ltd.
  • VF-5N dust collector manufactured by Amano Co., Ltd.
  • 1.5 kg of aluminum hydroxide manufactured by Nippon Light Metal Co., Ltd.
  • 1 kg of molybdenum trioxide manufactured by Nippon Muki Co., Ltd.
  • outside air (blowing speed: 150 L/min, outside air temperature: 25° C.) was introduced from the side and bottom surfaces of the firing furnace. After the molybdenum trioxide evaporated in the furnace, it was cooled near the dust collector and deposited as particles.
  • the molybdenum trioxide particles of Example 1 obtained above were subjected to crystal structure analysis by X-ray diffraction (XRD).
  • XRD X-ray diffraction
  • the results of the X-ray diffraction patterns are shown in FIG. 1 together with standard patterns for ⁇ crystals ( ⁇ -MoO 3 ) and ⁇ crystals ( ⁇ -MoO 3 ) of molybdenum trioxide.
  • ⁇ crystals ⁇ -MoO 3
  • ⁇ -MoO 3 ⁇ crystals of molybdenum trioxide.
  • a peak attributed to ⁇ crystals of MoO 3 and a peak attributed to ⁇ crystals of MoO 3 were observed, and no other peaks were observed.
  • the specific surface area (SA) of the molybdenum trioxide particles of Example 1 measured by the BET method was 97.7 m 2 /g.
  • Comparative Example 1 Commercially available molybdenum trioxide particles (manufactured by Nippon Inorganic Chemical Co., Ltd., lot number: 00501-C) were used as molybdenum trioxide particles of Comparative Example 1.
  • the molybdenum trioxide particles of Comparative Example 1 had a molybdenum trioxide (MoO 3 ) content (purity) of 99.9% by mass as measured by X-ray fluorescence (XRF).
  • the molybdenum trioxide particles of Comparative Example 1 were subjected to crystal structure analysis by XRD. Results are shown in FIG. A peak attributed to ⁇ -crystals of MoO 3 was observed, and no other peaks were observed. The peak intensity ratio ( ⁇ (011)/ ⁇ (021)) between the (011) plane of the ⁇ crystal of MoO3 and the (021) plane of the ⁇ crystal of MoO3 was zero.
  • the specific surface area (SA) of the molybdenum trioxide particles of Comparative Example 1 measured by the BET method was 0.9 m 2 /g.
  • Example 1-1 Preparation of aqueous dispersion>> [Example 1-1]
  • the molybdenum trioxide particles of Example 1 obtained above and water were mixed to obtain an aqueous dispersion of molybdenum trioxide particles.
  • the content of molybdenum trioxide particles is 25% by mass with respect to the total mass of the aqueous dispersion.
  • TK Homodisper was used to prepare a monomer emulsion. Then, 38.5 parts by mass of water was added to a flask equipped with a stirrer, a nitrogen inlet tube and a reflux condenser, and the temperature was raised to 50 ° C. while stirring and mixing under a nitrogen gas atmosphere. 0.2 parts by mass of sodium metabisulfite (hereinafter abbreviated as SBS) were added into the flask and dissolved. After that, the monomer emulsion prepared above, 4.0 parts by mass of APS aqueous solution (5% by mass), and 4.0 parts by mass of SBS aqueous solution (5% by mass) were dropped into the flask over 3 hours.
  • SBS sodium metabisulfite
  • Example 1-2 40 parts by mass of the molybdenum trioxide aqueous dispersion (solid content: 25% by mass) of Example 1-1 obtained above and an aqueous resin emulsion (resin content: 52% by mass) of acrylic resin (A-1) of Synthesis Example 1 ) were mixed with 11.5 parts by mass to prepare a coating composition.
  • the coating composition is applied to a 250 ⁇ m PET film using an applicator so that the content of molybdenum trioxide particles in the coating layer is 1 g / m 2 and dried to form a coating layer of the coating composition. It was used as a test sample. Transparency evaluation was performed on the obtained test samples. For transparency evaluation, the total light transmittance was measured with a haze meter manufactured by Nippon Denshoku Industries in accordance with JIS K7361. A total light transmittance (Tt) of 80% or more was evaluated as "A", and a total light transmittance of less than 80% was evaluated as "B".
  • Tt total light transmittance
  • the coating composition was applied to a glass plate using an applicator so that the content of molybdenum trioxide particles in the coating layer was 1 g/m 2 to form a coating layer of the coating composition, which was used as a test sample. . Antiviral evaluation was performed on the surface of the coating layer of the obtained test sample.
  • Antiviral evaluation was performed in accordance with JIS R 1756, targeting bacteriophage Q ⁇ . Light irradiation was carried out using a white fluorescent lamp at an illuminance of 1000 lx under a filter of Type B (N169: cuts wavelengths of 380 nm or less) specified in JIS R 1750. In JIS R 1756, a 1/500 concentration normal bouillon medium (1/500 NB) is used to prepare an inoculum phage solution, but 1/60 NB was used here.
  • the antiviral activity value (R) was expressed as a logarithmic value of the rate of decrease from the infectivity value at 0 hours immediately after inoculation (formula 1).
  • Antiviral activity value: R log (N0) - log (N) (Formula 1)
  • the light irradiation effect ( ⁇ R) was indicated by the difference in the antiviral activity value under light irradiation and in the dark (Formula 2).
  • Light irradiation effect: ⁇ R RL- RD (Formula 2)
  • RL Antiviral activity value under light irradiation RD: Antiviral activity value under dark conditions
  • the coating composition was applied to a glass plate using an applicator so that the content of molybdenum trioxide particles in the coating layer was 1 g/m 3 to form a coating layer of the coating composition, which was used as a test sample. .
  • Antibacterial evaluation was performed on the surface of the coating layer of the obtained test sample.
  • the antibacterial evaluation was performed using Sanai Biochecker FC (manufactured by Sanai Oil Co., Ltd.). Well water that had been allowed to stand at room temperature for one week in advance was dripped onto the medium surface of the San Biochecker, brought into contact with the coating layer of the glass plate or the glass plate having the coating layer of the test sample, and fixed with masking tape. This sample was cultured at 30° C. for 1 week, and B was given when colonies were formed in any medium, and A was given when colonies were not formed in any medium.
  • Table 3 shows the above evaluation results.
  • Both the molybdenum trioxide particles of Example 1 and the molybdenum trioxide particles of Comparative Example 1 had excellent antiviral activity and antibacterial activity, indicating that they can be used as antibacterial and antiviral agents.
  • the test sample to which the coating composition containing the molybdenum trioxide particles of Example 1 was applied had better transparency than the test sample to which the coating composition containing the molybdenum trioxide particles of Comparative Example 1 was applied. rice field.
  • the molybdenum trioxide particles of Example 1 have a larger BET specific surface area than the molybdenum trioxide particles of Comparative Example 1. From this, it is speculated that the molybdenum trioxide particles of Example 1 can exhibit antiviral activity and/or antibacterial activity in a smaller amount. That is, the molybdenum trioxide particles of Example 1 are antibacterial agents capable of exhibiting excellent antiviral activity and/or antibacterial activity while maintaining transparency with a smaller content than the molybdenum trioxide particles of Comparative Example 1. It was suggested to be an antiviral agent.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Materials Engineering (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
PCT/JP2022/013002 2021-03-24 2022-03-22 抗菌抗ウイルス剤、コーティング組成物、樹脂組成物、コーティング層及び成形体 Ceased WO2022202762A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202280023637.5A CN117042613A (zh) 2021-03-24 2022-03-22 抗菌抗病毒剂、涂覆组合物、树脂组合物、涂覆层和成型体
JP2023509172A JPWO2022202762A1 (https=) 2021-03-24 2022-03-22

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021050496 2021-03-24
JP2021-050496 2021-03-24

Publications (1)

Publication Number Publication Date
WO2022202762A1 true WO2022202762A1 (ja) 2022-09-29

Family

ID=83397381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2022/013002 Ceased WO2022202762A1 (ja) 2021-03-24 2022-03-22 抗菌抗ウイルス剤、コーティング組成物、樹脂組成物、コーティング層及び成形体

Country Status (3)

Country Link
JP (1) JPWO2022202762A1 (https=)
CN (1) CN117042613A (https=)
WO (1) WO2022202762A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024166341A1 (ja) * 2023-02-10 2024-08-15 三菱電機株式会社 抗ウイルス性コーティング膜、抗ウイルス性コーティング膜の製造方法及びコーティング物品

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119432139A (zh) * 2024-11-20 2025-02-14 天津灯塔涂料工业发展有限公司 一种钼基复合材料、抗菌防腐涂料及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019182846A (ja) * 2018-03-30 2019-10-24 地方独立行政法人神奈川県立産業技術総合研究所 抗ウイルス剤
JP2020533172A (ja) * 2017-09-15 2020-11-19 ヘコソル ゲーエムベーハー 抗菌コーティング

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533172A (ja) * 2017-09-15 2020-11-19 ヘコソル ゲーエムベーハー 抗菌コーティング
JP2019182846A (ja) * 2018-03-30 2019-10-24 地方独立行政法人神奈川県立産業技術総合研究所 抗ウイルス剤

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CORDT ZOLLFRANK; KAI GUTBROD; PETER WECHSLER; JOSEF PETER GUGGENBICHLER;: "Antimicrobial activity of transition metal acid MoOprevents microbial growth on material surfaces", MATERIALS SCIENCE AND ENGINEERING C, ELSEVIER SCIENCE S.A., CH, vol. 32, no. 1, 22 September 2011 (2011-09-22), CH , pages 47 - 54, XP028112650, ISSN: 0928-4931, DOI: 10.1016/j.msec.2011.09.010 *
MESTL G., HERZOG B., SCHLOEGL R., KNOEZINGER H.: "Mechanically Activated MoO3. 1. Particle Size, Crystallinity, and Morphology", LANGMUIR, AMERICAN CHEMICAL SOCIETY, US, vol. 11, no. 8, 1 August 1995 (1995-08-01), US , pages 3027 - 3034, XP009539897, ISSN: 0743-7463, DOI: 10.1021/la00008a030 *
SHAFAEI S., DöRRSTEIN J., GUGGENBICHLER J.P., ZOLLFRANK C.: "Cellulose acetate-based composites with antimicrobial properties from embedded molybdenum trioxide particles", LETTERS IN APPLIED MICROBIOLOGY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 64, no. 1, 1 January 2017 (2017-01-01), GB , pages 43 - 50, XP055802778, ISSN: 0266-8254, DOI: 10.1111/lam.12670 *
SUNADA, KAYANO; HATAYAMA, YASUYOSHI; NAGAI, TAKESHI; ISHIGURO, HITOSHI: "Testing pertaining to anti-virus activity of metal oxide under visible light", KISTEC ANNUAL RESEARCH REPORT, KANAGAWA INSTITUTE OF INDUSTRIAL SCIENCE AND TECHNOLOGY (KISTEC), JP, vol. 2019, 31 July 2019 (2019-07-31), JP, pages 153 - 155, XP009540171 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024166341A1 (ja) * 2023-02-10 2024-08-15 三菱電機株式会社 抗ウイルス性コーティング膜、抗ウイルス性コーティング膜の製造方法及びコーティング物品
JPWO2024166341A1 (https=) * 2023-02-10 2024-08-15

Also Published As

Publication number Publication date
CN117042613A (zh) 2023-11-10
JPWO2022202762A1 (https=) 2022-09-29

Similar Documents

Publication Publication Date Title
JP6040021B2 (ja) 抗菌抗ウイルス性組成物及びその製造方法
JP5646855B2 (ja) シリコーン樹脂組成物
WO2022202762A1 (ja) 抗菌抗ウイルス剤、コーティング組成物、樹脂組成物、コーティング層及び成形体
US6479141B1 (en) Photocatalytic coating composition and product having photocatalytic thin film
TW200404045A (en) Titanium dioxide pigment and method for producing the same, and resin composition using the same
JP2008274047A (ja) 熱線遮蔽塩化ビニルフィルム製造用組成物およびその製造方法、並びに、熱線遮蔽塩化ビニルフィルム
JP2020158367A (ja) 近赤外線吸収性材料、近赤外線吸収性層及び近赤外線吸収性部材
KR20210102253A (ko) 유기 무기 하이브리드 적외선 흡수 입자 제조 방법, 유기 무기 하이브리드 적외선 흡수 입자
JPWO2017221833A1 (ja) 組成物、及び化合物
JP2011065000A (ja) プラズマディスプレイパネル用近赤外線吸収フィルターとその製造方法およびプラズマディスプレイパネル
JP2022067282A (ja) 抗菌剤、抗菌性部材、及び使用方法
TW201620966A (zh) 含有鈦酸鹽奈米粒子之可溶液處理的ｈｒｉ（高折射率）光學膜
JPWO2004089829A1 (ja) 複合化酸化インジウム粒子およびその製造方法ならびに導電性塗料、導電性塗膜および導電性シート
JP7259231B2 (ja) 粒子状シリカ及びその製造方法
CN109311691A (zh) 化合物、分散液组合物及树脂组合物
JP2020152831A (ja) 抗菌坑カビ用塗料、抗菌坑カビ用部材
JP2011063484A (ja) 近赤外線遮蔽材料微粒子とその製造方法および近赤外線遮蔽材料微粒子分散体と近赤外線遮蔽体
JP5327848B2 (ja) 紫外線遮蔽用分散体および紫外線遮蔽用コーティング組成物
JP6413969B2 (ja) 日射遮蔽体形成用分散液および当該分散液を用いた日射遮蔽体
EP4269356A1 (en) Heat ray-blocking resin sheet material
TWI918815B (zh) 熱射線屏蔽樹脂片材
JP2024039723A (ja) 抗菌抗ウイルス剤、コーティング組成物、樹脂組成物、コーティング層及び成形体
KR20120095383A (ko) 차열제 조성물
JP2015017012A (ja) 油性分散液並びに薄膜及びその製造方法
JP6949304B2 (ja) 熱線吸収成分含有マスターバッチおよびその製造方法、熱線吸収透明樹脂成形体、並びに熱線吸収透明積層体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22775546

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023509172

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 202280023637.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22775546

Country of ref document: EP

Kind code of ref document: A1